The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Impact of MRD in FLT3+ AML: results from CHRYSALIS
Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the results of the Phase I/II CHRYSALIS study (NCT02014558), specifically the impact of peripheral blood measurable residual disease (MRD) on overall survival following treatment with gilteritinib, the first single-agent therapy for relapsed/refractory acute myeloid leukemia (AML) patients with FLT3 mutations. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Perl suggests a potential association between an MRD negative status and longer survival in patients with FLT3-mutated AML.
